Novelion Therapeutics Inc (NVLN):企業の財務・戦略的SWOT分析

【英語タイトル】Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C0269)・商品コード:DATA904C0269
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:49
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Novelion Therapeutics Inc (NVLN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Novelion Therapeutics Inc (Novelion), formerly QLT Inc, is a biopharmaceutical company that focuses on the development and commercialization of products and solutions for the treatment of people living with rare diseases. The company’s two marketed products are Lomitapide, a small molecule microsomal triglyceride transfer protein inhibitor offered under the brand name JUXTAPID, and Metreleptin, a recombinant analog of human leptin offered under the brand name MYALEPT. It also possesses another product candidate, zuretinol acetate, an oral synthetic retenoid for use in treatment of inherited retinal disease. The company operates along with its subsidiaries across North America, South America, Europe and Asia. Novelion is headquartered in Vancouver, British Columbia, Canada.

Novelion Therapeutics Inc Key Recent Developments

Jul 12,2018: EdgePoint Investment Group Acquires Shares of Common Stock of Novelion Therapeutics
Jul 03,2018: Novelion Therapeutics Names Mark Corrigan As Executive Chair Of The Board Of Directors
May 10,2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results
Mar 15,2018: Novelion Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results
Feb 28,2018: Novelion Therapeutics Observes Rare Disease Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Novelion Therapeutics Inc – Key Facts 6
Novelion Therapeutics Inc – Key Employees 7
Novelion Therapeutics Inc – Key Employee Biographies 8
Novelion Therapeutics Inc – Major Products and Services 9
Novelion Therapeutics Inc – History 10
Novelion Therapeutics Inc – Company Statement 12
Novelion Therapeutics Inc – Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 16
Company Overview 16
Novelion Therapeutics Inc – Business Description 17
Product Category: Lomitapide 17
Overview 17
Performance 17
Product Category: Metreleptin 17
Overview 17
Performance 18
Geographical Segment: Brazil 18
Performance 18
Geographical Segment: Other Foreign countries 18
Performance 18
Geographical Segment: The US 18
Performance 18
R&D Overview 18
Novelion Therapeutics Inc – SWOT Analysis 19
SWOT Analysis – Overview 19
Novelion Therapeutics Inc – Strengths 19
Novelion Therapeutics Inc – Weaknesses 20
Novelion Therapeutics Inc – Opportunities 21
Novelion Therapeutics Inc – Threats 22
Novelion Therapeutics Inc – Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios – Capital Market Ratios 24
Financial Ratios – Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios – Interim Ratios 29
Financial Ratios – Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Novelion Therapeutics Inc, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
May 10, 2018: Novelion Therapeutics Reports First Quarter 2018 Financial Results 34
Feb 28, 2018: Novelion Therapeutics Observes Rare Disease Day 35
Jan 30, 2018: Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals 36
Jan 24, 2018: Novelion Therapeutics Announces Cost Reduction Plans and Capital Structure Review 37
Dec 04, 2017: Novelion Therapeutics Appoints Michael Price as Senior Vice President and Chief Financial Officer 38
Nov 21, 2017: Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice 39
Nov 09, 2017: Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change 40
Oct 31, 2017: Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer 42
Oct 12, 2017: Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D 43
Sep 11, 2017: Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors 44
Section 6 – Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Novelion Therapeutics Inc, Key Facts 6
Novelion Therapeutics Inc, Key Employees 7
Novelion Therapeutics Inc, Key Employee Biographies 8
Novelion Therapeutics Inc, Major Products and Services 9
Novelion Therapeutics Inc, History 10
Novelion Therapeutics Inc, Other Locations 14
Novelion Therapeutics Inc, Subsidiaries 14
Novelion Therapeutics Inc, Key Competitors 23
Novelion Therapeutics Inc, Ratios based on current share price 24
Novelion Therapeutics Inc, Annual Ratios 25
Novelion Therapeutics Inc, Annual Ratios (Cont...1) 26
Novelion Therapeutics Inc, Annual Ratios (Cont...2) 27
Novelion Therapeutics Inc, Interim Ratios 29
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32
Novelion Therapeutics Inc, Recent Deals Summary 33
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48

List of Figures
Novelion Therapeutics Inc, Performance Chart (2013 - 2017) 28
Novelion Therapeutics Inc, Ratio Charts 30
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31
Novelion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

★調査レポート[Novelion Therapeutics Inc (NVLN):企業の財務・戦略的SWOT分析] (コード:DATA904C0269)販売に関する免責事項を必ずご確認ください。
★調査レポート[Novelion Therapeutics Inc (NVLN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆